CN1201736C - Slow-releasing metronidazole prepn for position of colon - Google Patents
Slow-releasing metronidazole prepn for position of colon Download PDFInfo
- Publication number
- CN1201736C CN1201736C CN 02125545 CN02125545A CN1201736C CN 1201736 C CN1201736 C CN 1201736C CN 02125545 CN02125545 CN 02125545 CN 02125545 A CN02125545 A CN 02125545A CN 1201736 C CN1201736 C CN 1201736C
- Authority
- CN
- China
- Prior art keywords
- metronidazole
- colon
- slow
- tablet
- release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a slow-releasing metronidazole preparation for anti-anaerobic bacteria medicines, particularly to a slow-releasing colon location preparation. The slow-releasing preparation uses a colon position medicine releasing technology to directly and slowly release medicines on focus parts.
Description
Technical field
The present invention relates to a kind of slow releasing preparation of anti-anaerobic agent metronidazole, particularly the conlon targeting slow releasing preparation.
Background technology
Metronidazole is that a pair of most of anaerobe has the antibacterials of strong antibiotic effect.The treatment that is widely used in infecting.At present, the metronidazole pharmaceutical preparation of having gone on the market both at home and abroad has multiple, mainly contains common tablet, capsule, injection and common slow releasing preparation (U.S. goes on the market, and commodity are called Flagyl ER, and the patent No. is WO:9520383).In recent years, the report of useful clinically metronidazole treatment colitis, colitis is a kind of disease that is difficult to cure of pilosity, main at present employing conservative treatment uses antibiotics or anti-inflammatory hormone simultaneously.In treatment colitis was used, common metronidazole oral formulations was difficult to arrive the colon position owing to absorb at gastric, can't obtain satisfied effect to the treatment of colitis.
The present invention adopts colon locating administrated technology, and metronidazole is made the conlon targeting slow releasing preparation, makes medicine can directly act on lesions position, has solved the difficult problem of clinical practice.
Summary of the invention
According to the release mechanism of different dosing system, the colon targeting drug administration system mainly can be divided into three major types:
A, PH dependent form medicine-releasing system: as 5-ASA colon enteric coatel tablets.The bion difference of this type of medicine-releasing system is bigger than normal, and studies have shown that has 90% targeting reliability of positioning approximately.
B, time lag medicine-releasing system: as the colon locating administrated time control micropill of 5-ASA.Medicine is generally 3-4h in small intestinal section retention time, designs the segmented intestine targeted system of time lag type based on this point, guarantees that medicine begins to discharge after leaving stomach 3-4h, but because the gastric emptying time irregular, so the medication individual variation is big.
C, flora trigger medicine-releasing system: the enzyme that utilizes colonic microflora to produce acts on lapping or sustained-release agent (as guar gum) and causes release, as the albendazole colon tablet.But metronidazole should not be prepared into this type of release mode, because of the powerful killing action of metronidazole to anaerobe, make the metronidazole that discharges kill a large amount of antibacterials, the enzyme that is produced by bacterium has just disappeared, do not had the effect of these enzymes, follow-up administration just can't disengage.
The present invention adopts the A system that metronidazole is made the conlon targeting slow releasing preparation; this slow releasing preparation can be slow releasing tablet or slow releasing capsule; its principle is label, granule or the micropill that earlier medication preparation is become to meet sustained releasing character in the colon medium, wraps in all insoluble resin molding in gastric juice, the small intestinal more outward.Behind the drug oral,,, thereby guarantee quantitatively to be transported in the colon medicine because the protection of PH dependent form resin although medicine has big individual variation in the duration of runs of harmonization of the stomach small intestinal, can guarantee that all medicine does not discharge in the harmonization of the stomach small intestinal at the little intestinal segment of harmonization of the stomach; When medicine arrived ascending colon, resin was dissolved in the 1h left and right sides, and this moment, medicated core began to discharge medicine by the slow release rule.The running of medicine in colon is a process slowly, about its average colon about 20h duration of runs, because medicine is made into the slow release form, thereby can guarantee that medicine is transported to whole colon system (ascending colon, transverse colon and descending colon) more reposefully.The segmented intestine targeted slow releasing agent of making by this principle of metronidazole, higher to the specificity of treatment colitis, bigger raising curative effect, and side effect reduces greatly.And only need be administered once in 1st, biological compliance improves, and consumption reduces.
The main preparation methods of slow releasing preparation of the present invention has two kinds:
1, earlier according to the preparation method of conventional matrix sustained release tablet, adopt sustained-release agent and make slow-releasing granules after metronidazole mixes, be pressed into matrix sustained release tablet after, outsourcing PH dependent form enteric resin again; Or slow-releasing granules packed in the special-purpose Capsules of colon.
2, earlier press the micropill preparation method, metronidazole made micropill, wrap one deck sustained-release coating layer earlier, reach satisfactory slow release effect after, wrap the molten resin of one deck PH dependent form colon again.
The available sustained-release agent of the present invention comprises:
A, cellulose family: as hypromellose, ethyl cellulose, methylcellulose, cellulose acetate etc.
B, alginic acid salt: as sodium alginate etc.
C, resinae: as various polyacrylic resins, Hydroxypropyl methyl cellulose phtalate, cellulose acetate phthalate rope etc.
D, melt erosion property adjuvant: as hydrogenated vegetable oil, Cera Flava, paraffin, natural gum, pectin etc.
This project available in gastric juice, small intestinal all insoluble slow (control) release coating material and comprise:
Phthalic acid hypromellose ester, cellulose acetate-phthalate, Lac, ethyl cellulose, polyacrylic resin etc.
Slow releasing preparation of the present invention, metronidazole content wherein is every 50mg-1000mg, all the other are slow-release material, all insoluble material and medicine acceptable carrier in gastric juice, small intestinal, sheet focuses on 100mg-1500mg, or the content of metronidazole counts 50-1000 by weight, and slow-release material, all insoluble material and medicine acceptable carrier are 20-500 in gastric juice, small intestinal.
Below be that slow releasing preparation of the present invention is carried out preliminary release and the experiment of body internal dynamics, with effect and the effect that proves slow releasing preparation of the present invention.
Experimental example one. the drug release determination of metronidazole conlon targeting slow releasing tablet (capsule), micropill:
Method: press CP2000 appendix XC first method, rotating speed 100 commentaries on classics/min, 37 ± 0.5 ℃ of concentration, UV method working sample is in the trap of each time point, and the mensuration wavelength is 277nm, presses C
6H
9N
3O
3Absorptance be 377 to calculate stripping quantities.
Determination data is seen attached list.
Wherein: medium one: be simulated gastric fluid (hydrochloric acid of 0.1mole).
Medium two: be simulated intestinal fluid (phosphate buffer of PH6.8).
Medium three: be artificial colonic fluid (phosphate buffer of PH7.8, CP2000 appendix regulation).
Table one. metronidazole conlon targeting slow releasing agent prescription table (unit: g)
Table two. drug release determination tables of data (%)
Can find out by last table release data, the present invention's product has in one's power satisfied the requirement of colon positioning and slow release, wherein tablet and micropill are more excellent, and capsule is owing to the reason of the colon special glue softgel shell of buying, when PH6.8, have a small amount of several thing to disengage, but the medicine more than 90% has also reached the purpose of colon positioning and slow release.
Experimental example two. the pharmacokinetics feature of metronidazole location colon slow releasing tablet:
1. distribution situation in the body behind the drug oral
1.1 method:
1.1.1 administration and working sample preparation:
Give rabbit 20mg/kg with the medicine oral administration, different time after administration: 1,3,4,6,12,16 totally 6 time points put to death respectively and tried rabbit, get stomach, small intestinal, caecum and ascending colon, transverse colon, descending colon section, after the content that washes out each section with distilled water carries out homogenate, to certain volume, get that wherein certain proportion is centrifugal with the distilled water standardize solution, collect supernatant, be evaporated to do after, with the mobile phase dissolving, with the filtering with microporous membrane of 0.5um, filtrate is measured with the HPLC method, calculates the distribution total amount of each position metronidazole.
1.1.2 chromatographic condition:
ODS C18 post (5 μ 4.6mm * 25cm); Mobile phase is methanol: water=40: 60; Flow velocity 1.0ml/min, detector wavelength 315nm; Sampling volume 20ul.In the mensuration of every batch sample, all need to make of blank serum simultaneously the standard curve of 3 concentration (2.3,5.2,8.1).Sample concentration (y) calculating is a according to this batch standard curve, and the b value is calculated sample chromatogram peak area (x) substitution regression equation y=bx ten a and get.
1.2 result
Table three. each section of gastrointestinal tract distribution situation (mg) behind metronidazole positioning and slow release sheet (sheet three) oral administration
Time
(h) stomach-intestinal caecum ascending colon transverse colon descending colon
1 - - - - - -
3 - - - - - -
4 - - 0.32±0.12 0.12±.05 - -
6 - - 0.54±0.08 5.24±1.17 1.15±0.32 -
12 - - 0.10±0.06 3.17±1.04 6.34±2.17 0.68±0.12
16 - - - 1.32±0.25 2.17±1.06 4.87±1.87
Table four. each section of gastrointestinal tract distribution situation (mg) behind the metronidazole positioning and slow release micropill oral administration
Time
(h) stomach-intestinal caecum ascending colon transverse colon descending colon
1 - - - - - -
3 - - - - - -
4 - - 0.41±0.16 0.23±0.11 - -
6 - - 0.67±0.08 6.27±2.45 2.14±1.06 -
12 - - 0.41±0.06 3.62±1.71 8.17±3.42 1.52±0.71
16 - - - 1.22±1.07 3.25±2.12 5.97±2.66
Table five. each section of gastrointestinal tract distribution situation (mg) behind the metronidazole ordinary tablet oral administration
Time
(h) stomach-intestinal caecum ascending colon transverse colon descending colon
1 13.1±2.65 5.62±1.32 - - - -
3 8.03±2.44 4.87±0.21 1.48±0.31 - - -
4 3.71±0.72 3.25±0.43 0.71±0.21 0.64±0.18 - -
6 2.19±0.36 1.79±0.83 0.54±0.11 1.27±0.29 0.36±0.08 -
12 1.75±0.27 0.87±0.16 0.21±0.33 0.49±0.15 - -
16 0.46±0.15 0.69±0.21 0.13±0.04 0.38±0.09 - -
2. the pharmacokinetic parameter behind the drug oral
2.1 method
2.1.1 administration and sampling
Give rabbit 20mg/kg with the medicine oral administration, different time is gathered blood after administration, separates and makes serum, gets serum 0.2ml in the 5ml centrifuge tube, the chloroformic solution that adds entry, phosphate buffer and 5% isopropyl alcohol, hybrid extraction is 5 minutes on blender, and organic layer is drawn in centrifugal back, uses the 0.5um organic membrane filter, filter liquor splashes in the point end test tube, blowing air dries up in the water-bath, and residue carries out quantitative analysis with the dissolving of 0.5ml mobile phase with HPLC.
2.1.2 chromatographic condition:
ODS C18 post (5 μ 4.6mm * 25cm); Mobile phase is methanol: water=40: 60; Flow velocity 1.0ml/min, detector wavelength 315nm; Sampling volume 20ul.In the mensuration of every batch sample, all need to make of blank serum simultaneously the standard curve of 3 concentration (2.3,5.2,8.1).Sample concentration (y) calculating is a according to this batch standard curve, and the b value is calculated sample chromatogram peak area (x) substitution regression equation y=bx ten a and get.
2.2 result
The pharmacokinetic parameter measurement result of metronidazole conlon targeting slow releasing tablet and micropill and ordinary tablet is as follows:
Parameter sheet three micropill ordinary tablets
Lag?time(h) 6.1±1.24 5.8±1.06 0.5±0.21
K
a 0.63±0.22 0.71±0.18 1.62±0.36
K
e 0.61±0.14 0.65±0.17 0.64±0.11
T
max 10.34±3.53 8.26±2.19 0.81±0.28
C
max(ug/ml) 0.48±0.16 0.59±0.11 14.3±3.46
AUC(mg·h·L
-1)?3.73±1.12 4.52±1.74 37.6±10.28
From above result, Metric 21 and the pellet made with the slow-released system of conlon targeting can make medicine be discharged into each position of colon, and make each Duan Jun of colon that one period that drug level is higher be arranged, thereby make the medicine acting surface wider, no matter which section colon is inflamed all can obtain the effective treatment.Because medicine is less in gastrointestinal tract release, make medicine less simultaneously, avoided unnecessary untoward reaction by the amount that blood circulation absorbs.Because bibliographical information is arranged, and (Nantong Medical College's journal 1991,11 (2): 172) metronidazole can enter brain by blood brain barrier and causes spiritual neurotoxicity reaction such as encephalitis syndrome.Mainly in the little intestinal absorption of harmonization of the stomach, the ratio of medicine arrival colon was less, have only by blood circulation and carry, so colitis site of pathological change drug level is not enough, can not reach effective therapeutic purposes after ordinary tablet was oral.
By pharmacokinetic parameter, medicine enters blood circulation speed and slows down, and the blood peak concentration is low, and is therefore favourable to avoiding systemic side effects, and that ordinary tablet enters blood circulation is very fast, the peak concentration height, and the bioavailability height can produce certain side effect.
Specific embodiments
The present invention is described further by the following examples.
Embodiment 1: the preparation of metronidazole sustained-release label:
Prescription: metronidazole: 600g ethyl cellulose: 150g
Hypromellose (4000cps) 200g calcium hydrogen phosphate: 140g
Dextrin: 80g micropowder silica gel: 10g
Operation: supplementary material is crossed 80 mesh sieves (pulverizing in case of necessity) earlier, take by weighing metronidazole, ethyl cellulose, hypromellose, calcium hydrogen phosphate and dextrin by recipe quantity, in mixer, mixed 10 minutes, the ethanol of adding 70% is an amount of, after making suitable soft material, granulate with 20 mesh sieves, behind 50-60 ℃ of hot air drying of wet grain, add SiO
2Mixing, 18 mesh sieve granulate.
It is every label that contains metronidazole 400mg (200mg) that this granule is pressed into specification with tablet machine.
Embodiment 2: the preparation two of metronidazole sustained-release label:
Prescription: metronidazole: 600g ethyl cellulose: 100g
Hypromellose (4000cps) 150g calcium hydrogen phosphate: 80g
Dextrin: 260g micropowder silica gel: 10g
Operation: identical with example 1.
Embodiment 3: the preparation three of metronidazole sustained-release label:
Prescription: metronidazole: 600g base cellulose: 90g
Hypromellose (4000cps) 110g calcium hydrogen phosphate: 90g
Micropowder silica gel: 10g
Operation: identical with example, the tabletting specification is an every label that contains metronidazole 400mg/ sheet and 200mg/ sheet.
Embodiment 4: the preparation four of metronidazole sustained-release label:
Prescription: metronidazole: 600g sodium alginate: 130g
Calcium hydrogen phosphate: 100g dextrin: 60g
Micropowder silica gel: 10g
Operation: and tabletting, identical with example 3.
Embodiment 5: the preparation five of metronidazole sustained-release label:
Prescription: metronidazole: 600g polyacrylic resin (II, III) powder: 80g
Calcium hydrogen phosphate: 100g dextrin: 110g
Micropowder silica gel: 10g
Operation: tabletting, with example 4.
Embodiment 6: the preparation six of metronidazole sustained-release tablets:
Prescription: metronidazole: 600g castor oil hydrogenated: 180g
Micropowder silica gel: 10g magnesium stearate: 10g
Operate: castor oil hydrogenated is heated to make in water-bath melt fully, the metronidazole of 80 mesh sieves had been pulverized in adding under the insulation, mixed 3～5 minutes under the insulation, remove the water-bath of heating, cooling while stirring under the room temperature, cross 20 mesh sieves after being chilled to room temperature, can not then pulverize to make fully and pass through by the big grain of 20 mesh sieves if having; Abundant mixing after adding micropowder silica gel and the magnesium stearate.
Tabletting: be pressed into specification and be every and contain metronidazole and be: the label of 200mg and 400mg.
Embodiment 7: the preparation of metronidazole sustained-release micropill:
3000g metronidazole, 450g sucrose, 300g dextrin are pulverized the back cross 120 mesh sieves, mix homogeneously.
Get mixed powder 500g and put in the coating pelletizing machine (BZJ-360M, sky, Beijing people company), prepare 40-50 order master batch with 3% polyvinylpyrrolidone ethanol liquid, 40 ℃ of hot blast temperatures, binding agent hydrojet speed 5ml/ minute.Master batch sieves after 50-60 ℃ of drying.
To go up system 40-50 order master batch and put in the coating pelletizing machine, the limit adds mixed powder limit spray binding agent, up to making 20-24 purpose micropill, sieves after the drying.
To go up system 20-40 order micropill and weigh in the rearmounted high-efficiency coating machine, press film coating method bag sustained-release coating layer, and make weightening finish (by 20-24 order ball core) reach 10-15% and get final product.Behind 40 ℃ of hot air drying 4 ~ 6h of made micropill, promptly get the conlon targeting sustained-release micro-pill capsules in the hollow capsule of packing into.
Sustained release coating liquid: homemade polyacrylic acid II resin and III resin are pressed 1: 1 mixed, be made into the concentration of 5% (w/v) with 95% ethanol, every 1000ml coating solution adds 2ml, and PEG400 is as porogen, and the 2ml dibutyl phthalate gets final product as plasticizer.
Embodiment 8: the preparation of metronidazole conlon targeting slow releasing tablet
Routine 1-example 6 made labels are put in the high-efficiency coating machine, pressed the film coating method, parcel PH dependent form resin, 40 ℃ of hot blasts, hydrojet speed is 5ml/ minute, 40 rev/mins of rotating speeds, coating weightening finish (label meter) 3～4%) can obtain the conlon targeting slow releasing tablet corresponding with embodiment 1-6.
The preparation of the molten PH dependent form of colon resin coating solution:
Take by weighing 50g polyacrylic resin (Eudragit S-100), pour in the ethanol of 1000ml 95%, add the 3ml dibutyl phthalate again as plasticizer, stir make complete molten after, standby.
Embodiment 9: the preparation of metronidazole conlon targeting slow releasing capsule:
Routine 1-example 6 made slow-releasing granules quantitatively pack into colon with in the hollow capsule, specification 200mg/ grain, and obtain the conlon targeting slow releasing capsule corresponding with embodiment 1-6.
Claims (1)
1, a kind of metronidazole compositions of slow release of conlon targeting, said composition is by metronidazole, slow-release material, all insoluble material and medicine acceptable carrier are formed in the gastric juice small intestinal, said composition is prepared into metronidazole the label that meets sustained releasing character in the colon medium, wrap all insoluble material in the gastric juice small intestinal again on the surface, make tablet, it is characterized in that, described tablet, its prescription is composed as follows:
Label prescription: metronidazole 600g
Ethyl cellulose 150g
Hypromellose 4000cps 200g
Calcium hydrogen phosphate 140g
Dextrin 80g
Micropowder silica gel 10g
The coating prescription:
Polyacrylic resin Eudragit S-100 50g
95% ethanol 1000ml
Dibutyl phthalate 3ml
More than 1500 every of Pei Fang amount manufacturing contains tablet or 3000 every tablet tablet that contains the 200mg metronidazole of 400mg metronidazole.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02125545 CN1201736C (en) | 2002-07-19 | 2002-07-19 | Slow-releasing metronidazole prepn for position of colon |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02125545 CN1201736C (en) | 2002-07-19 | 2002-07-19 | Slow-releasing metronidazole prepn for position of colon |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1398587A CN1398587A (en) | 2003-02-26 |
| CN1201736C true CN1201736C (en) | 2005-05-18 |
Family
ID=4745585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02125545 Expired - Lifetime CN1201736C (en) | 2002-07-19 | 2002-07-19 | Slow-releasing metronidazole prepn for position of colon |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1201736C (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20041295A1 (en) * | 2004-06-25 | 2004-09-25 | Cosmo Spa | ORAL ANTI-MICROBIAL PHARMACEUTICAL COMPOSITIONS |
| GB0607534D0 (en) * | 2006-04-13 | 2006-05-24 | Univ London Pharmacy | Colonic drug delivery formulation |
| EP2144599B1 (en) * | 2007-03-02 | 2010-08-04 | Farnam Companies, Inc. | Sustained release pellets comprising wax-like material |
| CN102600103B (en) * | 2012-03-02 | 2016-02-03 | 北京科信必成医药科技发展有限公司 | Capsule shells of a kind of colon positioning release and preparation method thereof |
-
2002
- 2002-07-19 CN CN 02125545 patent/CN1201736C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1398587A (en) | 2003-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101278932B (en) | Sustained release medicinal compositions containing Zaltoprofen, preparation method and application thereof | |
| CN1023293C (en) | Controlling-release preparation | |
| CN1134108A (en) | Beads for controlled release and pharmaceutical preparation contg. same | |
| CN1178650C (en) | Multiple unit controlled non-independent release pharmaceutical preparations and method for preparing same | |
| CN1630513A (en) | Hydrodynamically balancing oral drug delivery system with biphasic release | |
| CN1931137A (en) | Masked berberine hydrochloride micro pill and its prepn | |
| CN100350913C (en) | Colonic release composition | |
| CN1081029C (en) | Sustained-release metal valproate tablets | |
| CN1839846A (en) | Levofloxacin slow release micropill, its preparation method and uses | |
| CN1679592A (en) | Antipyretic and analgetic aspirin enteric-coated preparation and production thereof | |
| CN1326733A (en) | Colon-releasing oral preparation and its preparing method | |
| CN1201736C (en) | Slow-releasing metronidazole prepn for position of colon | |
| CN1285738A (en) | Novel oral dosage form for carvedilol | |
| CN101045053A (en) | Slow-releasing micro-pills of sophocarpidine and its preparing method | |
| CN1823804A (en) | Clamycin fast release micropill and its preparation method | |
| CN101032462A (en) | Mexiletine Hydrochloride slow release reagent and preparing method thereof | |
| CN1248693C (en) | Sustained release formulation of glucosamine salt, its preparation and usage | |
| CN1698623A (en) | Dispersed composition of anti-hepatitis B virus drugs in non-crystalline form and pharmaceutical preparation thereof | |
| CN1946376A (en) | Coated tablet composition and method of manufacturing the same | |
| CN106806353B (en) | Iguratimod sustained-release capsule and preparation method thereof | |
| CN1919185A (en) | Compound ammonium glycyrrhizinato S dispersed tablet and its preparing process | |
| CN1529587A (en) | Medicine bisacodyl granular composition comprising dung softening poloxamer and coated with enteric-coatel casing | |
| CN1883473A (en) | An enteric coated tablet of dulouxetine | |
| CN1066186A (en) | The pharmaceutical formulation that contains dirithromycin | |
| CN1903869A (en) | Tibifudine derivative salt and its preparation method and pharmaceutical application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: BUCHANG MEDICAL SCIENCE & TECHNOLOGY DEVELOPING C Free format text: FORMER OWNER: ANHUI PROV. INST. OF PHARMACOLOGY Effective date: 20070330 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20070330 Address after: 710075 Shaanxi city of Xi'an province high tech high road No. 50 Nanyang International Building, 20 floor Patentee after: Xianyang Buchang Pharmaceutical Technology Development Co.,Ltd. Address before: 230022 No. 202, Mount Huangshan Road, Hefei, Anhui Patentee before: ANHUI INST OF MATERIA MEDICA |
|
| ASS | Succession or assignment of patent right |
Owner name: SHANXI BUCHANG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: BUCHANG MEDICAL SCIENCE + TECHNOLOGY DEVELOPING CO., LTD., XIANYANG CITY Effective date: 20100108 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20100108 Address after: Box section 123 West Weiyang road in Xianyang City Patentee after: Shaanxi Buchang Pharmaceuticals Co.,Ltd. Address before: Shaanxi city of Xi'an province high tech high road No. 50 Nanyang International Building, 20 floor Patentee before: Xianyang Buchang Pharmaceutical Technology Development Co.,Ltd. |
|
| CX01 | Expiry of patent term |
Granted publication date: 20050518 |
|
| CX01 | Expiry of patent term |